Related Experiment Videos
Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer
Yoshiaki Yamamoto1, Hideyasu Matsuyama, Tomoko Furuya
1Department of Urology, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan.
Summary
Centrosome hyperamplification (CH) predicts recurrence in bladder cancer. Detecting CH offers key prognostic information for nonmuscle invasive bladder cancer patients, improving survival predictions.
Area of Science:
- Oncology
- Genetics
- Cell Biology
Background:
- Centrosome hyperamplification (CH) is linked to chromosomal instability in bladder cancer.
- Investigating CH as a prognostic biomarker is crucial for patient outcomes.
Purpose of the Study:
- To determine if centrosome hyperamplification (CH) can serve as a prognostic biomarker in bladder cancer patients.
- To assess the relationship between CH and tumor characteristics, recurrence, and progression.
Main Methods:
- Immunohistochemistry was used to evaluate CH in 50 bladder cancer samples.
- Numerical chromosome aberrations and 20q13 gain were assessed using fluorescence in situ hybridization.
- CH-positive cases were defined as >5% of cells with ≥3 centrosomes, with preliminary validation in cell lines showing 20q13 gain and Aurora-A overexpression.
Main Results:
- CH was detected in 60% of patients (CH+).
- CH+ patients showed significant differences in tumor number, grade, recurrence, and progression compared to CH- patients.
- Multivariate analysis identified CH+ as a strong predictor of tumor recurrence in nonmuscle invasive bladder cancer (pTa and pT1).
Conclusions:
- Centrosome hyperamplification (CH) detection provides significant prognostic information for bladder cancer.
- CH status is a key indicator for predicting tumor recurrence, particularly in nonmuscle invasive bladder cancer.